Clinical Trial: A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07725939) titled 'A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis' on July 21.

Brief Summary: The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD with chronic bronchitis.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Intervention: BIOLOGICAL...